MedTrace Logo

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT05967416 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-12-20

No results posted yet for this study

Summary

The goal of this study is to test SIRPant-M (RB-1355) , an autologous cell therapy, alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are being tested. The main question this study aims to answer is if SIRPant-M alone or in combination with radiotherapy is safe and well-tolerated.

Conditions

  • Refractory Non-Hodgkin Lymphoma
  • Relapsed Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL

SIRPant-M

Autologous activated macrophage cell therapy manufactured from peripheral blood mononuclear cells given by intratumoral injection

RADIATION

External-beam radiotherapy (XRT)

Radiotherapy given by external beam to the IT-injected lesion only

Sponsors & Collaborators

  • SIRPant Immunotherapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Jelle Kijlstra, MD, MBA · BobcatBio, p/k/a SIRPant Immunotherapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-17
Primary Completion
2025-06-30
Completion
2025-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05967416 on ClinicalTrials.gov